Home Cart Sign in  
Chemical Structure| 482-44-0 Chemical Structure| 482-44-0

Structure of Imperatorin
CAS No.: 482-44-0

Chemical Structure| 482-44-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Imperatorin is a naturally occuring multiple-target inhibitor of NOS with IC50 value of 9.2 μM, BChE with IC50 value of 31.4 μM, a potent calcium antagonist on vascular smooth muscle. It is also a weak agonist of TRPV1 with EC50 of 12.6±3.2 μM.

Synonyms: Ammidin; Marmelosin; NSC 402949

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Imperatorin

CAS No. :482-44-0
Formula : C16H14O4
M.W : 270.28
SMILES Code : C/C(C)=C\COC1=C2C(C=CC(O2)=O)=CC3=C1OC=C3
Synonyms :
Ammidin; Marmelosin; NSC 402949
MDL No. :MFCD00016881
InChI Key :OLOOJGVNMBJLLR-UHFFFAOYSA-N
Pubchem ID :10212

Safety of Imperatorin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293-hOATP1B3 100 μmol/L 2-5 min To evaluate whether TDE, IPT, and ISP are substrates of hOATP1B3, results showed that TDE is a substrate of hOATP1B3 Acta Pharm Sin B. 2020 Sep;10(9):1646-1657.
S2-hOAT3 100 μmol/L 2-5 min To evaluate whether TDE, IPT, and ISP are substrates of hOAT3, results showed that all three can be transported by hOAT3 Acta Pharm Sin B. 2020 Sep;10(9):1646-1657.
MDCK-hOAT1 100 μmol/L 2-5 min To evaluate whether IPT and ISP are substrates of hOAT1, results showed that IPT and ISP are substrates of hOAT1 Acta Pharm Sin B. 2020 Sep;10(9):1646-1657.
THP-1 cells 6.25–25 μM 24 hours To assess the effect of IMP on LPS-induced inflammatory response. IMP significantly reduced the production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Br J Pharmacol. 2018 Sep;175(17):3563-3580.
LS174T cells 6.25–25 μM 48 hours To assess the effect of IMP on CYP3A4 and MDR1 expression. IMP dose-dependently increased mRNA and protein levels of CYP3A4 and MDR1. Br J Pharmacol. 2018 Sep;175(17):3563-3580.
HCT116 cells 6.25–25 μM 24 hours To assess the effect of IMP on PXR-modulated CYP3A4 promoter activity. IMP significantly increased CYP3A4 promoter activity in a dose-dependent manner. Br J Pharmacol. 2018 Sep;175(17):3563-3580.
Human osteosarcoma cells U2OS 131.4 μM (24h), 116.3 μM (48h) 24h, 48h To evaluate the inhibitory effect of Imperatorin on osteosarcoma cell proliferation, results showed that Imperatorin significantly inhibited the proliferation of U2OS cells in a dose- and time-dependent manner. Cancer Cell Int. 2021 Dec 19;21(1):689.
Human osteosarcoma cells 143B 118.7 μM (24h), 90.0 μM (48h) 24h, 48h To evaluate the inhibitory effect of Imperatorin on osteosarcoma cell proliferation, results showed that Imperatorin significantly inhibited the proliferation of 143B cells in a dose- and time-dependent manner. Cancer Cell Int. 2021 Dec 19;21(1):689.
DAOY cells 10 μM, 20 μM 24 hours To evaluate the effect of IMP on DAOY cell proliferation, results showed that IMP significantly inhibited DAOY cell proliferation and downregulated GLI1 and PTCH1 expression. Drug Des Devel Ther. 2024 Nov 20;18:5307-5322.
Light II cells 10 μM, 20 μM 36 hours To evaluate the inhibitory effect of IMP on the Hh signaling pathway, results showed that IMP significantly inhibited Shh- and SAG-induced GLI-luciferase activity. Drug Des Devel Ther. 2024 Nov 20;18:5307-5322.
Primary microglia 10, 30, 50 μM 2 h pretreatment followed by 24 h LPS treatment To evaluate the effects of IMP on neuroinflammation, the results showed that IMP suppressed LPS-induced microglial activation and pro-inflammatory cytokines release. CNS Neurosci Ther. 2022 Jan;28(1):116-125.
KYSE30 cells 80 µM 24 hours Imperatorin significantly reduced TGFβ2 mRNA expression Adv Sci (Weinh). 2020 Jul 1;7(16):2000925.
KYSE150 cells 80 µM 24 hours Imperatorin significantly reduced TGFβ2 mRNA expression Adv Sci (Weinh). 2020 Jul 1;7(16):2000925.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Kunming mice Oral 20 mg/kg Single dose, observed at 1, 2, and 4 hours To evaluate the effect of IPT on the distribution of TDE in tissues, results showed that IPT significantly increased the concentration of TDE in blood and brain, and decreased in liver and kidney Acta Pharm Sin B. 2020 Sep;10(9):1646-1657.
C57BL/6 mice DSS-induced colitis model Gavage 25, 50, 100 mg/kg Once daily for 10 days To assess the effect of IMP on DSS-induced colitis. IMP significantly ameliorated body weight loss, bloody diarrhea, and colon shortening, and reduced histological damage. Br J Pharmacol. 2018 Sep;175(17):3563-3580.
BALB/c nude mice PDAC PDX model Oral 50 mg/kg Twice a week for 3 weeks The combination of imperatorin and gemcitabine significantly inhibited the growth of PDX tumors and reduced the expression of Ki67 and PCNA Oncogene. 2024 Jul;43(31):2405-2420
BALB/c-nu mice Subcutaneous tumor-transplanted nude mouse model Intraperitoneal injection 5 mg/kg Every other day, total 5 times To evaluate the inhibitory effect of Imperatorin on osteosarcoma growth in vivo, results showed that Imperatorin significantly reduced tumor volume and weight with no obvious toxicity to normal tissues. Cancer Cell Int. 2021 Dec 19;21(1):689.
Nude mice DAOY xenograft model Oral 50 mg/kg Once daily for 38 days To evaluate the inhibitory effect of IMP on xenograft tumor growth, results showed that IMP significantly inhibited tumor growth and downregulated GLI1 and phosphorylated STAT3 expression. Drug Des Devel Ther. 2024 Nov 20;18:5307-5322.
C57BL/6J mice Transient middle cerebral artery occlusion (tMCAO) model Intraperitoneal injection 5 mg/kg Administered at 30 min, 24 h, and 48 h post-reperfusion To evaluate the effects of IMP on ischemic brain injury, the results showed that IMP reduced infarct volume and improved neurological deficits. CNS Neurosci Ther. 2022 Jan;28(1):116-125.
Nude mice ESCC metastasis model Oral 25 or 50 mg/kg Three times a week Imperatorin significantly reduced lung metastasis in a dose-dependent manner Adv Sci (Weinh). 2020 Jul 1;7(16):2000925.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.00mL

7.40mL

3.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories